4//SEC Filing
Scott John K Jr. 4
Accession 0001437749-22-010726
CIK 0000810509other
Filed
May 2, 8:00 PM ET
Accepted
May 3, 7:12 PM ET
Size
11.7 KB
Accession
0001437749-22-010726
Insider Transaction Report
Form 4
Scott John K Jr.
10% Owner
Transactions
- Purchase
Series G Redeemable Preferred Stock
2022-04-10+3,260→ 3,260 total - Sale
Series E Redeemable Convertible Preferred Stock
2022-04-10$2.30/sh−50,000$115,000→ 0 totalExercise: $2.30From: 2021-03-02Exp: 2022-09-02→ Common Stock (2,173,913 underlying) - Purchase
Series F Redeemable Convertible Preferred Stock
2022-04-10$0.80/sh+1,740$1,392→ 1,740 totalExercise: $0.80From: 2022-04-10→ Common Stock (2,175,000 underlying) - Award
Common Stock
2022-04-30+2,500→ 8,093,395 total
Holdings
- 10,139(indirect: By Spouse)
Common Stock
Footnotes (5)
- [F1]Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of monthly non-employee director fees.
- [F2]Issuance deferred at the request of the Reporting Person.
- [F3]Includes 2,639 shares of Common Stock owned by the Reporting Person's spouse and 7,500 shares of Common Stock owned by the Reporting Person's children. The Reporting Person may be deemed to have shared voting and/or dispositive power with respect to such shares.
- [F4]Series E Redeemable Convertible Preferred Stock, par value $.001 per share, was exchanged for Series F Redeemable Convertible Preferred Stock, par value $.001 per share, and Series G Redeemable Preferred Stock, par value $.001 per share.
- [F5]Series F Redeemable Convertible Preferred Stock, par value $.001 per share, is convertible at any time and has no expiration date.
Documents
Issuer
NAVIDEA BIOPHARMACEUTICALS, INC.
CIK 0000810509
Entity typeother
Related Parties
1- filerCIK 0001753763
Filing Metadata
- Form type
- 4
- Filed
- May 2, 8:00 PM ET
- Accepted
- May 3, 7:12 PM ET
- Size
- 11.7 KB